Krebs, HA, Henseleit, K. Untersuchungen über die harnstoffbildung im tierkorper. Hoppe-Seyler's Z Physiol Chem. 1932;210:325–332CrossRefGoogle Scholar

Shih, VE. Hereditary urea-cycle disorders. Grisolia, S., Báguena, R., Mayor, F., eds. The Urea Cycle, John Wiley, New York, 367–414, 1976Google Scholar

Morizono, H, Caldovic, L, Shi, D, Tuchman, M. Mammalian N-acetylglutamate synthase. Mol Genet Metab. 2004;81(Suppl 1):S4–S11CrossRefGoogle ScholarPubMed

Brusilow, SW, Maestri, NE. Urea cycle disorders: Diagnosis, pathophysiology, and therapy. Adv Pediatr. 1996;43:127–170Google ScholarPubMed

Summar, ML, Dobbelaere, D, Brusilow, S, Lee, B. Diagnosis, symptoms, frequency and mortality of 260 patients with urea cycle disorders from a 21-year, multicentre study of acute hyperammonaemic episodes. Acta Paediatr. 2008;97(10):1420–1425CrossRefGoogle ScholarPubMed

Nassogne, MC, Heron, B, Touati, G, Rabier, D, Saudubray, JM. Urea cycle defects: Management and outcome. J Inherit Metab Dis. 2005;28(3):407–414CrossRefGoogle ScholarPubMed

Summar, ML, Barr, F, Dawling, S, Smith, W, Lee, B, Singh, RH, Rhead, WJ, Sniderman King, L, Christman, BW. Unmasked adult-onset urea cycle disorders in the critical care setting. Crit Care Clin. 2005;21:S1–S8CrossRefGoogle ScholarPubMed

Enns, GM, Berry, SA, Berry, GT, Rhead, WJ, Brusilow, SW, Hamosh, A. Survival after treatment with phenylacetate and benzoate for urea-cycle disorders. N Engl J Med. 2007;356(22):2282–2292CrossRefGoogle ScholarPubMed

Enns, GM. Neurologic damage and neurocognitive dysfunction in urea cycle disorders. Semin Pediatr Neurol. 2008;15(3):132–139CrossRefGoogle ScholarPubMed

Colombo, JP, Peheim, E, Kretschmer, R, Dauwalder, H, Sidiropoulos, D. Plasma ammonia concentrations in newborns and children. Clin Chim Acta. 1984;138(3):283–291CrossRefGoogle ScholarPubMed

Gropman, AL, Summar, M, Leonard, JV. Neurological implications of urea cycle disorders. J Inherit Metab Dis. 2007;30(6):865–879CrossRefGoogle ScholarPubMed

Brusilow, SW. Hyperammonemic encephalopathy. Medicine (Baltimore). 2002;81(3):240–249CrossRefGoogle ScholarPubMed

Norenberg, MD, Jayakumar, AR, Rama Rao, KV, Panickar, KS. New concepts in the mechanism of ammonia-induced astrocyte swelling. Metab Brain Dis. 2007;22(3–4):219–234CrossRefGoogle ScholarPubMed

Albrecht, J, Norenberg, MD. Glutamine: A Trojan horse in ammonia neurotoxicity. Hepatology. 2006;44(4):788–794CrossRefGoogle ScholarPubMed

Ratnakumari, L, Qureshi, IA, Butterworth, RF. Regional amino acid neurotransmitter changes in brains of spf/Y mice with congenital ornithine transcarbamylase deficiency. Metab Brain Dis. 1994;9(1):43–51CrossRefGoogle ScholarPubMed

Butterworth, RF. Glutamate transporter and receptor function in disorders of ammonia metabolism. Ment Retard Dev Disabil Res Rev. 2001;7(4):276–279CrossRefGoogle ScholarPubMed

Robinson, MB, Hopkins, K, Batshaw, ML, McLaughlin, BA, Heyes, MP, Oster-Granite, ML. Evidence of excitotoxicity in the brain of the ornithine carbamoyltransferase deficient sparse fur mouse. Brain Res Dev Brain Res. 1995;90(1–2):35–44CrossRefGoogle ScholarPubMed

Monfort, P, Munoz, MD, Felipo, V. Molecular mechanisms of the alterations in NMDA receptor-dependent long-term potentiation in hyperammonemia. Metab Brain Dis. 2005;20(4):265–274CrossRefGoogle ScholarPubMed

Bachmann, C, Braissant, O, Villard, AM, Boulat, O, Henry, H. Ammonia toxicity to the brain and creatine. Mol Genet Metab. 2004;81(Suppl 1):S52–S57CrossRefGoogle ScholarPubMed

Niemi, AK, Enns, GM. Sodium phenylacetate and sodium benzoate in the treatment of neonatal hyperammonemia. NeoReviews. 2006;7(9):e486–e495CrossRefGoogle Scholar

Lewis, HB. Studies in the synthesis of hippuric acid in the animal organism. J Biol Chem. 1914;18:225Google Scholar

Shiple, GJ, Sherwin, CP. Synthesis of amino acids in animal organisms I. Synthesis of glycocoll and glutamine in the human organism. J Am Chem Soc. 1922;44(3):618–624CrossRefGoogle Scholar

Batshaw, ML, MacArthur, RB, Tuchman, M. Alternative pathway therapy for urea cycle disorders: Twenty years later. J Pediatr. 2001;138(1 Suppl):S46–S54; discussion S54–S55CrossRefGoogle ScholarPubMed

Brusilow, SW, Valle, DL, Batshaw, M. New pathways of nitrogen excretion in inborn errors of urea synthesis. Lancet. 1979;2(8140):452–454CrossRefGoogle ScholarPubMed

Brusilow, SW, Danney, M, Waber, LJ, Batshaw, M, Burton, B, Levitsky, L, Roth, K, McKeethren, C, Ward, J. Treatment of episodic hyperammonemia in children with inborn errors of urea synthesis. N Engl J Med. 1984;310(25):1630–1634CrossRefGoogle ScholarPubMed

Green, TP, Marchessault, RP, Freese, DK. Disposition of sodium benzoate in newborn infants with hyperammonemia. J Pediatr. 1983;102(5):785–790CrossRefGoogle ScholarPubMed

Simell, O, Sipila, I, Rajantie, J, Valle, DL, Brusilow, SW. Waste nitrogen excretion via amino acid acylation: Benzoate and phenylacetate in lysinuric protein intolerance. Pediatr Res. 1986;20(11):1117–1121CrossRefGoogle ScholarPubMed

Bunchman, TE, Barletta, GM, Winters, JW, Gardner, JJ, Crumb, TL, McBryde, KD. Phenylacetate and benzoate clearance in a hyperammonemic infant on sequential hemodialysis and hemofiltration. Pediatr Nephrol. 2007;22(7):1062–1065CrossRefGoogle Scholar

Singh, RH, Rhead, WJ, Smith, W, Lee, B, King, LS, Summar, M. Nutritional management of urea cycle disorders. Crit Care Clin. 2005;21(4 Suppl):S27–S35CrossRefGoogle ScholarPubMed

Batshaw, ML, Brusilow, SW. Evidence of lack of toxicity of sodium phenylacetate and sodium benzoate in treating urea cycle enzymopathies. J Inherit Metab Dis. 1981;4(4):231CrossRefGoogle ScholarPubMed

Gershanik, J, Boecler, B, Ensley, H, McCloskey, S, George, W. The gasping syndrome and benzyl alcohol poisoning. N Engl J Med. 1982;307(22):1384–1388CrossRefGoogle ScholarPubMed

Thibault, A, Samid, D, Cooper, MR, Figg, WD, Tompkins, AC, Patronas, N, Headlee, DJ, Kohler, DR, Venzon, DJ, Myers, CE. Phase I study of phenylacetate administered twice daily to patients with cancer. Cancer. 1995;75(12):2932–29383.0.CO;2-P>CrossRefGoogle ScholarPubMed

Batshaw, ML, Brusilow, S, Waber, L, Blom, W, Brubakk, AM, Burton, BK, Cann, HM, Kerr, D, Mamunes, P, Matalon, R, Myerberg, D, Schafer, IA. Treatment of inborn errors of urea synthesis: Activation of alternative pathways of waste nitrogen synthesis and excretion. N Engl J Med. 1982;306(23):1387–1392CrossRefGoogle ScholarPubMed

MacArthur, RB, Altincatal, A, Tuchman, M. Pharmacokinetics of sodium phenylacetate and sodium benzoate following intravenous administration as both a bolus and continuous infusion to healthy adult volunteers. Mol Genet Metab. 2004;81(Suppl 1):S67–S73CrossRefGoogle ScholarPubMed

Praphanphoj, V, Boyadjiev, SA, Waber, LJ, Brusilow, SW, Geraghty, MT. Three cases of intravenous sodium benzoate and sodium phenylacetate toxicity occurring in the treatment of acute hyperammonaemia. J Inherit Metab Dis. 2000;23(2):129–136CrossRefGoogle ScholarPubMed

Maestri, NE, Hauser, ER, Bartholomew, D, Brusilow, SW. Prospective treatment of urea cycle disorders. J Pediatr. 1991;119(6):923–928CrossRefGoogle ScholarPubMed

Uchino, T, Endo, F, Matsuda, I. Neurodevelopmental outcome of long-term therapy of urea cycle disorders in Japan. J Inherit Metab Dis. 1998;21(Suppl 1):151–159CrossRefGoogle ScholarPubMed

Bachmann, C. Outcome and survival of 88 patients with urea cycle disorders: A retrospective evaluation. Eur J Pediatr. 2003;162(6):410–416CrossRefGoogle ScholarPubMed

Tuchman, M, Lee, B, Lichter-Konecki, U, Summar, ML, Yudkoff, M, Cederbaum, SD, Derr, DS, Dias, GA, Seashore, MR, Lee, H-S, McCarter, RJ, Jeffrey, P, Krischer, JP, Batshaw, ML. Cross-sectional multicenter study of patients with urea cycle disorders in the United States. Mol Genet Metab. 2008;94:397–402CrossRefGoogle ScholarPubMed

Enns, GM, Millan, MT. Cell-based therapies for metabolic liver disease. Mol Genet Metab. 2008;95(1–2):3–10CrossRefGoogle ScholarPubMed

Raper, SE, Chirmule, N, Lee, FS, Wivel, NA, Bagg, A, Gao, GP, Wilson, JM, Batshaw, ML. Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol Genet Metab. 2003;80(1–2):148–158CrossRefGoogle Scholar

John, BA, Taylor, LM, Johnson, S, Lees, MJ, Johns, P, Gargosky, S, Dickinson, K. The disposition of HPN-100, a novel pharmaceutical under development for potential treatment of hyperammonemia, in Cynomolgus monkeys. Presented at American College of Medical Genetics Annual Meeting 2009; Abstract 66.

Lee, B, Mian, A, Shchelochkov, O, Martinez, T, Mokhtarani, M, Scharschmidt, B, et al. Phase 2 study of a novel ammonia scavenging agent in adults with urea cycle disorders. Presented at American College of Medical Genetics Annual Meeting 2009; Abstract 17.